Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Dongzheng Gai's research focuses on understanding the molecular mechanisms underlying multiple myeloma and related blood cancers. His work investigates how specific genes and proteins, such as TRIP13, NEK2, and CST6, influence tumor development, progression, and the associated bone disease characteristic of multiple myeloma. Gai has published research on the role of GPR109A in regulating osteoclastogenesis and bone resorption in mice, and how decreased bone resorption can be observed in specific mouse models with altered myeloid cell function. His recent publications also explore the potential of bispecific CAR-T cells targeting BCMA and CD24, as well as BCMA- and CST6-specific CAR T cells, for controlling multiple myeloma growth and suppressing osteolytic lesions in preclinical models. Additionally, Gai has contributed to research identifying gene signatures that can predict the progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma. He has an h-index of 8 and has authored 26 publications with 258 citations.
Metrics
- h-index: 8
- Publications: 26
- Citations: 258
Selected Publications
-
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)
-
Cystatin M/E ameliorates bone resorption through increasing osteoclastic cell estrogen influx (2024)
-
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)
-
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions (2023)
-
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023)
-
P-066 BCMA-CAR-T cells with synthetic circuits of CST6 lyse tumor cells and suppress osteolytic lesions in multiple myeloma (2023)
-
A gene signature can predict risk of MGUS progressing to multiple myeloma (2023)
-
Decreased bone resorption in Ezh2 myeloid cell conditional knockout mouse model (2023)
-
A Gene Signature Can Predict Risk of MGUS Progressing to Multiple Myeloma (2023)
-
A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance (2022)
-
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation (2022)
-
Deep-Sequencing Can be Used to Reconstruct and Extend Microarray-Based Classification and Risk Stratification for Multiple Myeloma (2021)
-
NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma (2021)
-
Ezh2 mediates epigenetic regulation of osteoclastogenesis and bone remodeling in mice (2021)
-
GPR109A mediates the effects of hippuric acid on regulating osteoclastogenesis and bone resorption in mice (2021)
Collaboration Network
Top Collaborators
- GPR109A mediates the effects of hippuric acid on regulating osteoclastogenesis and bone resorption in mice
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Decreased bone resorption in Ezh2 myeloid cell conditional knockout mouse model
Showing 5 of 12 shared publications
- TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 12 shared publications
- TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 12 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 12 shared publications
- TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 11 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- GPR109A mediates the effects of hippuric acid on regulating osteoclastogenesis and bone resorption in mice
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Decreased bone resorption in Ezh2 myeloid cell conditional knockout mouse model
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Showing 5 of 9 shared publications
- TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 8 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Showing 5 of 8 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 8 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 8 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 8 shared publications
- TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 7 shared publications
- TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Showing 5 of 7 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
- The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting CST6 Against Multiple Myeloma and Suppresses Osteolytic Lesions
Showing 5 of 7 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
- The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting CST6 Against Multiple Myeloma and Suppresses Osteolytic Lesions
Showing 5 of 7 shared publications
Similar Researchers
Based on overlapping research topics